BioSpace News Archive

Signals Analytics, the next-generation advanced analytics platform that leverages external data to uncover trends and predictive insights, today unveils its COVID-19 Playbook, providing access to critical market intelligence and trends surrounding potential treatments for the novel coronavirus

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and central nervous system (CNS) diseases and disorders with high unmet medical need, today announced a common stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC),

Repertoire Immune Medicines, a newly launched company working to unleash the curative power of the immune system to prevent and cure disease, today announced an investment from the JDRF T1D Fund, a venture philanthropy vehicle focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D).

Organogenesis Holdings Inc. (Nasdaq: ORGO), today announced that it will sponsor a March 26 WoundSource Webinar, “Taking Control of the Wound Healing Environment” led by Alisha Oropallo, MD, FACS, Medical Director of the Comprehensive Wound Healing Center and Hyperbarics at Northwell Health.

Only remote cardiac monitoring company whose proprietary connected system has FDA-approved indication to measure, analyze and report QT interval

Bio-Techne Corporation (NASDAQ:TECH) today shared news from clinical partners on the use of the ProteinSimple™-branded Ella ™ Automated Immunoassay platform in the fight against COVID-19. In a March 23, 2020 press release, the Icahn School of Medicine, Mount Sinai announced that they are utilizing Bio-Techne’s Ella Automated I

In addition to $1 million donation, brand plans to donate $1 for every use of hashtag #ShareASquare and provide one million rolls of Cottonelle over the next three months

Therapix Biosciences Ltd. announced today that the Company will host a conference call on Wednesday, April 22, 2020, at 4:30 PM EDT. ET

STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus

After continuously serving chemically dependent women since 1983 under the leadership of June Davis and Nancy Stofferahn, The Gables has reached an agreement to transfer ownership through a sale of its assets to the non-profit NUWAY Alliance.